| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Carnitine palmitoyl transferase 1 (CPT1)[1]
Malonyl Coenzyme A lithium salt targets enzymes involved in fatty acid and polyketide synthesis, including fatty acid synthase (FASN) and polyketide synthases. It acts as a substrate for these enzymes, providing two-carbon units for chain elongation. Malonyl-CoA is also a key regulator of fatty acid oxidation, acting as an inhibitor of carnitine palmitoyltransferase 1 (CPT1), thereby controlling the balance between fatty acid synthesis and oxidation. Accumulation of malonyl-CoA triggers a feedback loop that suppresses further fatty acid synthesis. |
|---|---|
| ln Vitro |
When myotubes are incubated with Malonyl Coenzyme A (in a polyamine carrier), both palmitate oxidation and insulin-stimulated glucose transport are inhibited [1].
In vitro, malonyl Coenzyme A lithium salt serves as a substrate for fatty acid synthase and other enzymes involved in lipid metabolism. It is used in biochemical assays to measure the activity of fatty acid synthase, acetyl-CoA carboxylase, and other enzymes. High levels of malonyl-CoA have been associated with cancer cell apoptosis, making it a compound of interest in cancer metabolism research. The compound shows concentration-dependent activity in enzyme assays. |
| ln Vivo |
In vivo, malonyl Coenzyme A lithium salt plays a critical role in metabolic regulation. It serves as a key intermediate in fatty acid synthesis and as a regulator of fatty acid oxidation through inhibition of CPT1. High levels of malonyl-CoA, resulting from fatty acid synthase inhibition, have been linked to cancer cell apoptosis in xenograft models. The compound's role in metabolic regulation makes it a valuable tool for studying metabolic diseases and cancer.
|
| Enzyme Assay |
The in vitro enzyme assay for malonyl Coenzyme A lithium salt typically involves measuring the activity of fatty acid synthase or acetyl-CoA carboxylase using radiolabeled or spectrophotometric methods. The enzyme is incubated with malonyl-CoA and other substrates (e.g., acetyl-CoA, NADPH) in assay buffer at 37°C for 10-30 minutes. Product formation (e.g., palmitate) is quantified by scintillation counting or spectrophotometry. Kinetic parameters such as Km and Vmax are determined from substrate concentration curves.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Myotubes Tested Concentrations: 10 μM Incubation Duration: 30 min Experimental Results: Prevented insulin-stimulated glucose transport and inhibited palmitate oxidation. For in vitro cell-based assays, cells (e.g., cancer cell lines, hepatocytes, or adipocytes) are cultured and treated with modulators of fatty acid synthesis. Malonyl-CoA levels are measured in cell lysates using LC-MS/MS or enzymatic assays. Fatty acid synthesis is assessed by measuring the incorporation of radiolabeled acetate or glucose into lipids. Cell viability and apoptosis are assessed using MTT or Annexin V assays. Metabolic flux analysis can be performed using stable isotope tracers. |
| Animal Protocol |
In vivo animal studies for malonyl Coenzyme A lithium salt are typically conducted in the context of metabolic research. Animal models of obesity, diabetes, or cancer are used to study the role of malonyl-CoA in metabolic regulation. Malonyl-CoA levels are measured in tissues such as liver, adipose tissue, and muscle using LC-MS/MS. Fatty acid synthesis and oxidation rates are assessed using isotope tracers. The compound itself is not administered as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of malonyl Coenzyme A lithium salt have not been characterized for therapeutic applications, as the compound is a metabolic intermediate and research reagent. The molecular weight is 853.58 g/mol and the molecular formula is C₂₄H₃₈N₇O₁₉P₃S·xLi. The compound is supplied as a lithium salt with a purity of ≥90%. Stability in solution may be limited and fresh solutions should be prepared for each experiment.
|
| Toxicity/Toxicokinetics |
Toxicology data for malonyl Coenzyme A lithium salt are limited. The compound is a naturally occurring metabolic intermediate and is generally considered to have low toxicity. However, as a research reagent, it has not been systematically evaluated for safety. Standard laboratory safety precautions should be followed when handling the compound. It is not intended for human use.
|
| References | |
| Additional Infomation |
Malonyl coenzyme A lithium salt is an organic molecular entity whose function is related to coenzyme A.
Malonyl Coenzyme A lithium salt is a coenzyme A derivative involved in fatty acid and polyketide synthesis. It serves as a two-carbon donor for chain elongation and as a regulator of fatty acid oxidation. The compound is a valuable research tool for studying lipid metabolism, metabolic regulation, and cancer metabolism. It is intended for research use only and is not approved for therapeutic applications. |
| Molecular Formula |
C24H38N7O19P3S.XLI
|
|---|---|
| Molecular Weight |
860.521420000001
|
| Exact Mass |
859.124
|
| CAS # |
108347-84-8
|
| Related CAS # |
Malonyl CoA;524-14-1
|
| PubChem CID |
16219642
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
55
|
| Complexity |
1490
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Li].CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(=O)O)O
|
| InChi Key |
OPIJLICRFQMMJH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H38N7O19P3S.Li/c1-24(2,19(37)22(38)27-4-3-13(32)26-5-6-54-15(35)7-14(33)34)9-47-53(44,45)50-52(42,43)46-8-12-18(49-51(39,40)41)17(36)23(48-12)31-11-30-16-20(25)28-10-29-21(16)31;/h10-12,17-19,23,36-37H,3-9H2,1-2H3,(H,26,32)(H,27,38)(H,33,34)(H,42,43)(H,44,45)(H2,25,28,29)(H2,39,40,41);
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
PBS: 10 mg/mL (adjust pH to 7.2)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1621 mL | 5.8104 mL | 11.6209 mL | |
| 5 mM | 0.2324 mL | 1.1621 mL | 2.3242 mL | |
| 10 mM | 0.1162 mL | 0.5810 mL | 1.1621 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
